Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

778 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Aggressive lymphoma subtype is a risk factor for venous thrombosis. Development of lymphoma - specific venous thrombosis prediction models.
Dharmavaram G, Cao S, Sundaram S, Ayyappan S, Boughan K, Gallogly M, Malek E, Metheny L, Tomlinson B, Otegbeye F, Lazarus HM, Cooper B, Fu P, de Lima M, Caimi PF. Dharmavaram G, et al. Among authors: lazarus hm. Am J Hematol. 2020 Aug;95(8):918-926. doi: 10.1002/ajh.25837. Epub 2020 May 8. Am J Hematol. 2020. PMID: 32311162 Free article.
A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia.
Cooper BW, Veal GJ, Radivoyevitch T, Tilby MJ, Meyerson HJ, Lazarus HM, Koc ON, Creger RJ, Pearson G, Nowell GM, Gosky D, Ingalls ST, Hoppel CL, Gerson SL. Cooper BW, et al. Among authors: lazarus hm. Clin Cancer Res. 2004 Oct 15;10(20):6830-9. doi: 10.1158/1078-0432.CCR-04-0097. Clin Cancer Res. 2004. PMID: 15501959 Clinical Trial.
High-dose carmustine, etoposide, and cisplatin for autologous stem cell transplantation with or without involved-field radiation for relapsed/refractory lymphoma: an effective regimen with low morbidity and mortality.
Wadhwa PD, Fu P, Koc ON, Cooper BW, Fox RM, Creger RJ, Bajor DL, Bedi T, Laughlin MJ, Payne J, Gerson SL, Lazarus HM. Wadhwa PD, et al. Among authors: lazarus hm. Biol Blood Marrow Transplant. 2005 Jan;11(1):13-22. doi: 10.1016/j.bbmt.2004.09.003. Biol Blood Marrow Transplant. 2005. PMID: 15625540 Free article. Clinical Trial.
Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients.
Lazarus HM, Koc ON, Devine SM, Curtin P, Maziarz RT, Holland HK, Shpall EJ, McCarthy P, Atkinson K, Cooper BW, Gerson SL, Laughlin MJ, Loberiza FR Jr, Moseley AB, Bacigalupo A. Lazarus HM, et al. Biol Blood Marrow Transplant. 2005 May;11(5):389-98. doi: 10.1016/j.bbmt.2005.02.001. Biol Blood Marrow Transplant. 2005. PMID: 15846293 Free article. Clinical Trial.
Randomised comparison of two B-cell purging protocols for patients with B-cell non-Hodgkin lymphoma: in vivo purging with rituximab versus ex vivo purging with CliniMACS CD34 cell enrichment device.
van Heeckeren WJ, Vollweiler J, Fu P, Cooper BW, Meyerson H, Lazarus HM, Simic A, Laughlin MJ, Gerson SL, Koç ON. van Heeckeren WJ, et al. Among authors: lazarus hm. Br J Haematol. 2006 Jan;132(1):42-55. doi: 10.1111/j.1365-2141.2005.05827.x. Br J Haematol. 2006. PMID: 16371019 Free article. Clinical Trial.
Influence of human leucocyte antigen disparity and graft lymphocytes on allogeneic engraftment and survival after umbilical cord blood transplant in adults.
van Heeckeren WJ, Fanning LR, Meyerson HJ, Fu P, Lazarus HM, Cooper BW, Tse WW, Kindwall-Keller TL, Jaroscak J, Finney MR, Fox RM, Solchaga L, Forster M, Creger RJ, Laughlin MJ. van Heeckeren WJ, et al. Among authors: lazarus hm. Br J Haematol. 2007 Nov;139(3):464-74. doi: 10.1111/j.1365-2141.2007.06824.x. Br J Haematol. 2007. PMID: 17910637 Free article. Clinical Trial.
778 results